Sector
PharmaceuticalsOpen
₹17Prev. Close
₹17.44Turnover(Lac.)
₹0.02Day's High
₹17.01Day's Low
₹1752 Week's High
₹27.7452 Week's Low
₹10.7Book Value
₹-14.28Face Value
₹10Mkt Cap (₹ Cr.)
17P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -23.56 | -22.37 | -20.62 | -17.36 |
Net Worth | -13.63 | -12.44 | -10.69 | -7.43 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 12.25 | 7.84 | 13.57 | 20.45 |
yoy growth (%) | 56.19 | -42.2 | -33.65 | 8.48 |
Raw materials | -8.74 | -4.52 | -6.84 | -10.4 |
As % of sales | 71.34 | 57.67 | 50.4 | 50.84 |
Employee costs | -3.1 | -3.22 | -4.93 | -5.3 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -3.99 | -3.68 | -3.18 | -1.18 |
Depreciation | -0.66 | -0.72 | -0.7 | -0.64 |
Tax paid | -0.96 | 0.83 | 0.67 | 0.41 |
Working capital | -5.79 | 5.62 | -2.44 | -2.57 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 56.19 | -42.2 | -33.65 | 8.48 |
Op profit growth | -19.05 | 12.27 | 2,443.81 | -109.04 |
EBIT growth | -15.71 | 12.46 | 327.74 | -209.11 |
Net profit growth | 74.64 | 13.08 | 227.43 | -2,127.21 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Vimal D Shah
Non Executive Director
Praveen Bafna
Independent Director
Angamuthu Vadivel
Company Sec. & Compli. Officer
Priyanka Lohiya
Additional Director
VENKATACHALAM SATHYA
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Norris Medicines Ltd
Summary
Norris Medicines Limited was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments. The Company was subsequently converted into Public Limited Company on March 7, 1992. The unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The Company got into the business in the year 1990. Commercial production of the formulation unit commenced in Nov.91. The production unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The project commence in March 1992. Thereafter, the Company came out with a Public Issue aggregating Rs. 5 Crore in December, 1993 to expand its existing capacity for tablets, capsules, etc, besides diversifying into bulk drugs and setting up an injectables unit. The project costing Rs 14.21 Crore was financed through loans and equity, which got completed in 1995.In 2006, the Company launched Diabetic & Cardiac products; launched Dental product in 2007; launched New Molecule Tolperisone with Paracetamol tablet in 2012; in 2013, it extended Anti malarial range with Artemether Lumefantrine tablet & dry syrup. During the year 2013-14, the Company undertook the upgradation of Sterile Injectable Plant. The Company is one of the leading Indian manufacturers of Injections and Medicinal formulations. The Company is engaged into Health Care Industry and operate 2 plants situated at GIDC, Ankleshwar, Gujarat. Both plants of th
Read More
The Norris Medicines Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹17 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Norris Medicines Ltd is ₹17.00 Cr. as of 09 May ‘25
The PE and PB ratios of Norris Medicines Ltd is 0 and -1.22 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Norris Medicines Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Norris Medicines Ltd is ₹10.7 and ₹27.74 as of 09 May ‘25
Norris Medicines Ltd's CAGR for 5 Years at 46.66%, 3 Years at -19.35%, 1 Year at 45.94%, 6 Month at -23.64%, 3 Month at -19.85% and 1 Month at 16.89%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.